

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. UCSF-085 CIP	SERIAL NO. 09/616,223
		APPLICANT Nadel et al.	
		FILING DATE July 14, 2000	GROUP 1635 Unassigned

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
J3	AN	5,525,625	06/11/96	Bridges et al.			
J3	AO	6,037,361	03/14/00	Roth et al.			

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
J3	AP	WO 97/19065	05/29/97	PCT			Yes No
J3	AQ	WO 97/45412	12/04/97	PCT			
	AR	WO 98/37881	09/03/98	PCT			
	AS	WO 99/01421	01/14/99	PCT			
	AT	WO 99/01426	01/14/99	PCT			
	AU	WO 99/32121	07/01/99	PCT			
	AV	WO 00/06560	02/10/00	PCT			
	AW	WO 00/06561	02/10/00	PCT			
	AX	WO 00/09485	02/24/00	PCT			
J3	AY	WO 00/17162	03/30/00	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

J3	AA	Donato et al (1989), "Tumor Necrosis Factor Modulates Epidermal Growth Factor Receptor Phosphorylation and Kinase Activity in Human Tumor Cells", <i>The Journal of Biological Chemistry</i> , Vol. 264(34): 20474-20481.
J3	AB	Desseyn et al. (1997), "Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat", <i>The Journal of Biological Chemistry</i> , Vol. 272(6): 3168-3178.

EXAMINER	<i>J3</i>	DATE CONSIDERED	<i>3-2-07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. UCSF-085 CIP	SERIAL NO. 09/616,223
		APPLICANT	Nadel et al.
		FILING DATE July 14, 2000	GROUP 1635 Unassigned
J3	AC	Goldstein et al. (1995), "Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model", <i>Clinical Cancer Research</i> , Vol. 1: 1311-1318.	
	AD	Kawamoto et al. (1983), "Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 80: 1337-1341.	
	AE	Kondapaka et al. (1996), "Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer", <i>Molecular and Cellular Endocrinology</i> , Vol. 117: 53-58.	
	AF	Levitski (1994), "Signal-transduction therapy, a novel approach to disease management", <i>Eur. J. Biochem.</i> , Vol. 226(1):1-13.	
	AG	Lorimer, et al. (1995), "Immunotoxins that Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors", <i>Clinical Cancer Research</i> , Vol. 1: 859-864.	
	AH	Petit et al. (1997), "Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2/neu Receptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells <i>in Vitro</i> and <i>in Vivo</i> ", <i>American Journal of Pathology</i> , Vol. 151(6): 1523-1530.	
	AI	Powis (1994), "Signaling pathways as targets for anticancer drug development", <i>Pharmac. Ther.</i> , Vol. 62:57-95.	
	AJ	Schmidt et al. (1996), "Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF α ", <i>British Journal of Cancer</i> , Vol. 74: 853-862	
	AK	Takeyama et al. (1998), "Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules", <i>Am. J. Physiol.</i> , Vol. 275:294-302.	
	AL	Temann et al. (1997), "A Novel Role for Murine IL-4 <i>In Vivo</i> : Induction of MUC5AC Gene Expression and Mucin Hypersecretion", <i>Am J. Respir. Cell Biol.</i> , Vol. 16:471-478.	
	AM	Ullrich et al. (1984), "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells." <i>Nature</i> , Vol. 309(5967):418-25.	
	AZ	Brown (1999), "Clinical Studies with matrix metalloproteinase inhibitors." <i>APMIS</i> , Vol. 107:174-180.	
	BA	Grandis, jr., et al. (1997), "Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells." <i>Oncogene</i> , Vol. 15(4):409-416.	
	BB	Kumar et al. (1998), "Cooperative interaction of autocrine and paracrine mitogens for airway epithelial cells." <i>Cell Biology and Toxicology</i> , Vol. 14(4):293-299.	
	BC	Lee et al. (2000), "Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals." <i>American Journal of Respiratory and Critical Care Medicine</i> , Vol. 161(6):1881-1886.	
	BD	Prenzel et al. (1999), "EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF." <i>Nature</i> , Vol. 402:884-888.	
	BE	Takeyama et al. (1999), "Epidermal growth factor system regulates mucin production in airways." <i>Proceedings of the National Academy of Sciences USA</i> , Vol. 96(6):3081-3086.	
	BF	Takeyama et al. (2000), "Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils." <i>Journal of Immunology</i> , Vol. 164(3):1546-1552.	
	BG	Wojtowicz-Praga et al. (1997), "Matrix metalloproteinase inhibitors." <i>Investigational New Drugs</i> , Vol. 15:61-75.	

F:\forms\word 2k forms\form PTO-1449.doc

EXAMINER J3	DATE CONSIDERED 3-2-07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**SUPPLEMENTAL
INFORMATION DISCLOSURE CITATION**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

ATTY. DOCKET NO. UCSF-085CIP	SERIAL NO. 09/616,223
APPLICANT	Nadel, et al.
FILING DATE July 14, 2000	GROUP Unassigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>JZ</i>	AA	Grandis et al. (July 24, 1997), "Inhibition of Epidermal Growth Factor Receptor Gene Expression and Function Decreases Proliferation of Head and Neck Squamous Carcinoma but not Normal Mucosal Epithelial Cells." <i>Oncogene</i> , Vol 15(4):406-416
-----------	----	--

EXAMINER	<i>JZ</i>	DATE CONSIDERED	<i>3-2-07</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/616,223
(use as many sheets as necessary)				Filing Date	July 14, 2000
Sheet	1	of	1	First Named Inventor	Nadel, et al.
				Group Art Unit	1614
				Examiner Name	Zara, Jane
				Attorney Docket Number	UCSF-085CIP

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
		—			Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴ Kind Code ⁵ (if known)		
		—			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ⁶	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		GUZMAN, et al. "Epidermal growth factor regulates expression of the mucous phenotype of rat tracheal epithelial cells", <i>Biochem. Biophys. Res. Com.</i> , (1995) Vol. 217(2): 412-418.			

Examiner Signature		Date Considered	3-2-07
--------------------	---	-----------------	--------

⁶EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	09/616,223
				Filing Date	July 14, 2000
				First Named Inventor	NADEL, JAY A.
				Art Unit	1635
				Examiner Name	ZARA, JANE
Sheet	1	of	1	Attorney Docket Number	UCSF-085CIP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**SUPPLEMENTAL
INFORMATION DISCLOSURE CITATION**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

ATTY. DOCKET NO.
UCSF085CIPSERIAL NO.
09/616,223

APPLICANT

Nadel et al.

FILING DATE
July 14, 2000

GROUP

1614 1635

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
J3	AA	WO 00/10588 A3	03/02/2000	PCT			Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

F:\DOCUMENT\UCSF\085cip\Supp.Form PTO-1449.doc

EXAMINER	DATE CONSIDERED
J3	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		10816159
	Filing Date		2004-03-31
	First Named Inventor		Jay A. NADEL
	Art Unit		1635
	Examiner Name		Jane J. Zara
	Attorney Docket Number		UCSF-085CON5

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
JB	1	6551989	B2	2003-04-22	NADEL et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
JB	1	760766	AU	B2	2000-03-14	NADEL et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button


NON-PATENT LITERATURE DOCUMENTS						Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10816159
	Filing Date	2004-03-31
	First Named Inventor	Jay A. NADEL
	Art Unit	1635
	Examiner Name	Jane J. Zara
	Attorney Docket Number	UCSF-085CON5

1			<input type="checkbox"/>
---	--	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	3-2-c7
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.



AUG 09 2004

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete If Known	
				<u>Application Number</u>	10/816,159
				<u>Filing Date</u>	March 31, 2004
				<u>First Named Inventor</u>	NADEL, JAY A.
				<u>Art Unit</u>	1813 1635
				<u>Examiner Name</u>	To Be Assigned
				<u>Attorney Docket Number</u>	UCSF-085CONS
Sheet	1	of	2		

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	3-2-07
-----------------------	---	--------------------	--------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. 6 Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
<p>Sheet 2 of 2</p>		<p>Application Number 10/816,159</p> <p>Filing Date March 31, 2004</p> <p>First Named Inventor NADEL, JAYA</p> <p>Group Art Unit 1614</p> <p>Examiner Name To Be Assigned</p>		<p>Attorney Docket Number UCSF-085CONS</p>	

OTHER ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JZ		Van Herwaarden et al., "The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease." Netherlands Journal of Medicine, 47 (1995): 45-48	
JZ		Amishma, M. et al., "Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway." American Journal of Respiratory and Critical Care medicine, Vol. 157, No. 6, June 1998, pgs. 1907-1912	

Examiner Signature		Date Considered	3-2-07
-----------------------	---	--------------------	--------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.